首頁 > 市場調查報告書 > 製藥

神經疾病疼痛

神經病變疼痛市場規模、佔有率和成長分析（按類型、產品類型、手術、技術、模式、購買方式和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1905876

神經病變疼痛市場規模、佔有率和成長分析（按類型、產品類型、手術、技術、模式、購買方式和地區分類）－2026-2033年產業預測

Neuropathic Pain Market Size, Share, and Growth Analysis, By Type, By Product Type, By Procedure, By Technology, By Modality, By Mode of Purchase, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，神經病變疼痛市場規模將達到 28.3 億美元，到 2025 年將達到 29.8 億美元，到 2033 年將達到 45.1 億美元，在預測期（2026-2033 年）內複合年成長率為 5.3%。

慢性疾病（尤其是糖尿病）盛行率的上升，以及人口老化，顯著加劇了神經病變疼痛的發生率。持續不斷的研發投入，致力於創新治療方法和藥物干預，進一步推動了這一趨勢，並促進了市場擴張。醫護人員和患者對有效管理神經病變疼痛方法的認知不斷提高，凸顯了這個細分市場的成長潛力。製藥公司積極推出新藥和治療方法，以滿足神經病變疼痛領域尚未滿足的需求，旨在改善治療效果和患者生活品質，市場因此蓬勃發展。綜上所述，這些因素預示著神經病變疼痛治療市場前景看好。

神經病變疼痛市場促進因素

糖尿病、各種癌症和神經系統疾病等慢性病的日益流行，顯著加劇了全球神經病變疼痛病例的增加。隨著人口老化，與神經病變疼痛相關的風險因素不斷上升，進一步推動了市場需求。此外，科學研究和開發的持續進步，在研發專門針對神經病變疼痛的創新藥物和治療方法發揮關鍵作用，從而拓展了治療選擇。慢性病盛行率的上升和醫療解決方案的進步，共同為有效應對神經病變疼痛的複雜問題創造了強勁的市場環境。

神經病變疼痛市場限制因素

神經病變疼痛市場面臨的主要阻礙因素源於診斷難題和疼痛評估固有的主觀性，這使得準確識別和測量神經病變疼痛變得複雜，並可能導致症狀漏報和管理不善。此外，先進治療方法和藥物成本的不斷上漲也會限制患者獲得治療的機會，尤其是在醫療預算緊張的地區。這些因素共同構成了有效治療和管理神經病變疼痛的重大障礙，最終影響患者的健康和整個市場的成長。

神經病變疼痛市場趨勢

神經病變疼痛市場正呈現出創新治療方法和藥物干預措施蓬勃發展的顯著趨勢，凸顯了該領域的動態演變。這項變化源自於持續不斷的研究和進步，旨在提高治療效果和改善患者預後。此外，遠端醫療正在改變神經病變疼痛管理的格局。這些技術能夠提供更便利、更個人化的醫療服務，確保患者獲得及時的診斷、持續的監測以及量身定做的治療方案，從而有效滿足其個別需求。創新與便利的結合正在重新定義疼痛管理策略，並有助於提高神經病變疼痛患者的生活品質。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer Inc.（USA）
Novartis AG（Switzerland）
Eli Lilly and Company（USA）
Johnson & Johnson（USA）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Astellas Pharma Inc.（Japan）
Abbott Laboratories（USA）
Medtronic plc（Ireland）
Boston Scientific Corporation（USA）
Biogen Inc.（USA）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
AbbVie Inc.（USA）
Grunenthal GmbH（Germany）
AstraZeneca PLC（UK）
Daiichi Sankyo Company, Limited（Japan）

結論與建議

簡介目錄

Product Code: SQMIG35D2215

Neuropathic Pain Market size was valued at USD 2.83 Billion in 2024 and is poised to grow from USD 2.98 Billion in 2025 to USD 4.51 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

The rising prevalence of chronic conditions, particularly diabetes, alongside an aging population, significantly contributes to the increasing incidence of neuropathic pain. This trend is further fueled by ongoing research and development efforts focused on innovative treatments and pharmaceutical interventions, fostering market expansion. Greater awareness among healthcare professionals and patients regarding effective management options for neuropathic pain highlights this growing sector. The market remains dynamic, with pharmaceutical companies actively launching new medications and therapeutic approaches aimed at addressing the unmet medical needs associated with neuropathic pain, enhancing treatment outcomes and improving patient quality of life. Overall, these factors indicate a promising outlook for the neuropathic pain treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neuropathic Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segments Analysis

Global Neuropathic Pain Market is segmented by Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel and region. Based on Type, the market is segmented into Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy and Proximal Neuropathy. Based on Product Type, the market is segmented into Rechargeable and Non-Rechargeable. Based on Procedure, the market is segmented into Invasive and Non-Invasive. Based on Technology, the market is segmented into Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation. Based on Modality, the market is segmented into Stationary and Portable. Based on Mode of Purchase, the market is segmented into Over-the-Counter Devices and Prescription-Based Devices. Based on Pain Type, the market is segmented into Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain and Coccydynia. Based on Indication, the market is segmented into Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy and Others. Based on Diagnosis, the market is segmented into Imaging, Blood Tests and Physical Examination. Based on Treatment, the market is segmented into Medications and Multimodal Therapy. Based on End User, the market is segmented into Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Third Party Distributor and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neuropathic Pain Market

The rising prevalence of chronic conditions such as diabetes, various cancers, and neurological disorders has significantly contributed to a growing number of neuropathic pain cases worldwide. As populations age, the associated risk factors for neuropathic pain increase, further driving demand in the market. Additionally, continuous advancements in scientific research and pharmaceutical development play a crucial role in creating innovative medications and therapies specifically targeting neuropathic pain, thereby improving treatment options. This combination of increasing chronic illness rates and advancements in medical solutions supports a robust market environment for addressing the complexities of neuropathic pain effectively.

Restraints in the Neuropathic Pain Market

A significant constraint in the neuropathic pain market arises from the challenges in diagnosis and the inherently subjective nature of pain assessment, which complicates the accurate identification and measurement of neuropathic pain. This can result in underreporting or insufficient management of the condition. Additionally, the elevated costs associated with advanced treatment options and medications can limit accessibility, particularly in regions where healthcare budgets are constrained. These factors combined create substantial barriers to effectively addressing and managing neuropathic pain, ultimately affecting both patients' welfare and the overall market growth.

Market Trends of the Neuropathic Pain Market

The neuropathic pain market is witnessing a significant trend towards the development of innovative treatment modalities and pharmaceutical interventions, underscoring the sector's dynamic evolution. This shift is driven by ongoing research and advancements that aim to enhance therapeutic efficacy and patient outcomes. Additionally, the proliferation of telehealth services and virtual health solutions is transforming the landscape of neuropathic pain management. These technologies facilitate more accessible and personalized care, enabling patients to receive timely diagnoses, continuous monitoring, and tailored treatment plans that effectively address their unique needs. This combination of innovation and accessibility is redefining pain management strategies, fostering better quality of life for individuals affected by neuropathic pain.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Neuropathic Pain Market Size by Type & CAGR (2026-2033)

Market Overview
Spinal Cord Stimulation (SCS) Devices
External Peripheral Nerve Stimulation
Transcutaneous Electrical Nerve Stimulation (TENS) Devices
Focal Neuropathy
Automatic Neuropathy
Proximal Neuropathy

Global Neuropathic Pain Market Size by Product Type & CAGR (2026-2033)

Market Overview
Rechargeable
Non-Rechargeable

Global Neuropathic Pain Market Size by Procedure & CAGR (2026-2033)

Market Overview
Invasive
Non-Invasive

Global Neuropathic Pain Market Size by Technology & CAGR (2026-2033)

Market Overview
Transcutaneous Electrical Nerve Stimulation
Transcranial Magnetic Stimulation
Respiratory Electrical Stimulation

Global Neuropathic Pain Market Size by Modality & CAGR (2026-2033)

Market Overview
Stationary
Portable

Global Neuropathic Pain Market Size by Mode of Purchase & CAGR (2026-2033)

Market Overview
Over-the-Counter Devices
Prescription-Based Devices

Global Neuropathic Pain Market Size by Pain Type & CAGR (2026-2033)

Market Overview
Peripheral Neuropathy
Entrapment Neuropathy
Phantom Limb Neuropathy
Trigeminal Neuralgia
Post Herpetic Neuralgia (PHN)
Post Traumatic Neuropathy
Foot Pain
Coccydynia

Global Neuropathic Pain Market Size by Indication & CAGR (2026-2033)

Market Overview
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Diabetic Neuropathy
Others

Global Neuropathic Pain Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Imaging
Blood Tests
Physical Examination

Global Neuropathic Pain Market Size by Treatment & CAGR (2026-2033)

Market Overview
Medications
Multimodal Therapy

Global Neuropathic Pain Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Home Healthcare
Ambulatory Surgical Centers
Research Organization
Others

Global Neuropathic Pain Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Direct Tender
Third Party Distributor
Others

Global Neuropathic Pain Market Size & CAGR (2026-2033)

North America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- US
- Canada
Europe (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments